The most recent Structure Therapeutics (GPCR) insider transaction: Crespo Blas Coll (Chief Medical Officer) had 10,626 shares withheld to cover tax worth about $124.01K on Sep 18, 2026, reported on Form 4 on Sep 22, 2026. So far in the quarter ending Dec 31, 2026, insider holdings showed no net buying or selling.
Across the past 12 months, Structure Therapeutics insiders reported no open-market purchases or sales.
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ltd Fil | Other | 0 | 6,473,761 | 6,473,761 | 33.0% | 09 Feb, 2023 |
| 2 | Llc Fmr | Other | 0 | 5,816,554 | 5,816,554 | 29.7% | 09 Feb, 2023 |
| 3 | Ramy Farid | Director | 0 | 3,260,495 | 3,260,495 | 16.6% | 09 Feb, 2023 |
| 4 | Jun Yoon | Chief Financial Officer | 1,401,656 | 0 | 1,401,656 | 7.1% | 22 Mar, 2026 |
| 5 | Raymond C Stevens | Chief Executive Officer | 1,401,593 | 0 | 1,401,593 | 7.1% | 22 Mar, 2026 |
| 6 | Crespo Blas Coll | Chief Medical Officer | 258,228 | 0 | 258,228 | 1.3% | 22 Sep, 2026 |
| 7 | Xichen Lin | Chief Scientific Officer | 228,960 | 0 | 228,960 | 1.2% | 02 Sep, 2026 |
| 8 | Matthew Lang | Coo Gc | 184,614 | 0 | 184,614 | 0.9% | 22 Apr, 2026 |
| 9 | Ashley Hall | Chief Development Officer | 155,187 | 0 | 155,187 | 0.8% | 22 Mar, 2026 |
| 10 | John Joseph Berrios | Chief Commercial Officer | 140,766 | 0 | 140,766 | 0.7% | 07 Aug, 2026 |
| 11 | Yingli Ma | Chief Technology Officer | 139,917 | 0 | 139,917 | 0.7% | 22 Mar, 2026 |
| 12 | Daniel G Welch | Director | 0 | 123,508 | 123,508 | 0.6% | 09 Feb, 2023 |
| 13 | Mark Allen Bach | Chief Medical Officer | 26,235 | 0 | 26,235 | 0.1% | 19 Mar, 2024 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 18 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed F | 10,626 | $11.67 | $124.01K | 270,252 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed C | 12,024 | $0.00 | $0 | 258,228 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Acquired C | 4,008 | $0.00 | $0 | 5,165 | Direct |
| 21 Sep, 2026 | Crespo Blas Coll | Chief Medical Officer | Disposed S | 4,008 | $36.15 | $144.87K | 1,157 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Acquired M | 17,817 | $0.34 | $6.06K | 246,777 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed C | 17,817 | $0.00 | $0 | 228,960 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed M | 17,817 | $0.00 | $0 | 125,081 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Acquired C | 5,939 | $0.00 | $0 | 5,939 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 1,300 | $45.86 | $59.62K | 4,639 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 4,539 | $47.20 | $214.25K | 100 | Direct |
| 01 Sep, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 100 | $47.83 | $4.78K | 0 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Acquired M | 11,817 | $0.34 | $4.02K | 240,777 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed C | 11,817 | $0.00 | $0 | 228,960 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed M | 11,817 | $0.00 | $0 | 142,898 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Acquired C | 3,939 | $0.00 | $0 | 3,939 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 3,020 | $53.13 | $160.46K | 919 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 519 | $54.20 | $28.13K | 400 | Direct |
| 18 Aug, 2026 | Xichen Lin | Chief Scientific Officer | Disposed S | 400 | $55.05 | $22.02K | 0 | Direct |
| 06 Aug, 2026 | John Joseph Berrios | Chief Commercial Officer | Acquired A | 140,766 | $0.00 | $0 | 140,766 | Direct |
| 06 Aug, 2026 | John Joseph Berrios | Chief Commercial Officer | Acquired A | 174,612 | $0.00 | $0 | 174,612 | Direct |